Navigation Links
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Date:9/10/2007

bitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel- Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, the likelihood of successful results from a clinical trial with Bicifadine, operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully launch a Phase IIb clinical trial with Bicifadine, recruit adequate participants for such a Phase IIb clinical trial, obtain positive trial results from a Phase IIb clinical trial, and our ability to successfully complete cost-effective pre-clinical trials for our DOS program, all of which will directly impact our ability to continue to fund our operations; our ability to meet anticipated development timelines for all of our drug candidates due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission and the London Stock Exchange, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-lo
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 In November 2012, ... Benefit Risk Evaluation Report (PBRER) in a new PSUR – ... post-authorization safety benefit-risk profile of a drug. Adopted in many ... , Present a comprehensive and critical analysis of ... , Highlight any new evidence of the potential ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... , NEW YORK , May 19 After ... 12 former Novartis sales reps $3.36 million in compensatory ... stronger dose of the same medicine.  Announcing the amount of punitive ... an additional $250 million for the gender discrimination it ...
... May 19 Volcano Corporation (Nasdaq: VOLC ... CE Mark approval for its PrimeWire PRESTIGE™ Pressure Guide ... and multi-vessel disease. This next generation pressure wire is ... and stand-alone physiology systems as well as various hemodynamic ...
... ,, ATLANTA , May 19 ... partnership to adapt the Sivix key computing fob and ... sensing safety solutions.  These solutions are based upon the ... sensing unit inside the helmet of an athlete, firefighter, ...
Cached Biology Technology:Novartis Class Awarded $250 Million in Punitive Damages 2Novartis Class Awarded $250 Million in Punitive Damages 3Novartis Class Awarded $250 Million in Punitive Damages 4Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 2Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 3Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 4Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 5Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... Genetic factors in African Americans with chronic kidney disease ... renal disease (ESRD) compared to white Americans, according to ... England Journal of Medicine . Researchers at Johns Hopkins ... two separate studies: the African American Study of Kidney ...
... shape or move with no power source other than ... led by the University of Pittsburgh. The researchers are ... converting light energy into mechanical work and potentially eliminating ... and power sources. "I like to compare this ...
... large family of cell-surface receptors that respond to ... factors such as epidermal growth factor (EGF) and ... neuronal guidance. Ligand binding stimulates the tyrosine kinase ... enzymes and adapter proteins that activate intracellular signaling ...
Cached Biology News:Gene puts African-Americans at higher risk for kidney failure 2Snap to attention: Polymers that react and move to light 2
... easy transformation of the budding yeast, Saccharoyces ... simply by mixing a plasmid DNA and ... No complicated steps, such as centrifugation or ... particularly well suited for high-throughput transformation of ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
Biology Products: